American Society of Hirudotherapy

Chronic Postsurgical Pain Syndrome (Investigational Adjunct)

Investigational adjunct for chronic postsurgical pain after surgical site healed; multimodal pain management including pharmacotherapy, physical therapy, and (for neuropathic features) interventional pain procedures remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for chronic postsurgical pain. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic postsurgical pain syndrome is investigational.
What evidence exists?
Tier C (investigational). No randomized or controlled study of leech therapy for chronic postsurgical pain was identified; the nearest reports found are two small uncontrolled Russian series, described in a 2004 monograph, in post-traumatic stump and gunshot-wound rehabilitation. Evidence-based therapy for chronic postsurgical pain (pain persisting >3 months after surgery): multimodal pain management including gabapentin/pregabalin, tricyclic antidepressants or SNRIs (duloxetine), topical lidocaine or capsaicin for neuropathic component, physical therapy, cognitive-behavioral therapy, and interventional procedures (nerve blocks, neuromodulation) for refractory cases.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over surgical scar areas
  • Local skin infection or, rarely, Aeromonas infection near a surgical wound
  • Allergic reaction to leech saliva (uncommon)
  • Worsening of neuropathic pain after the procedure
  • Risk if leech placed too close to surgical mesh or hardware
  • Permanent small scars added to surgical scar
  • Delay of multimodal pain management or pain psychology
Who should not consider this
  • Patients within 12 weeks of surgery (wound-healing concerns)
  • Patients with active surgical-site infection
  • Patients with prosthetic hardware or mesh at the proposed site (infection risk)
  • Patients with opioid use disorder (risk substitution rather than addressing root)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Patients who have not tried multimodal pharmacologic and physical therapy management
What to ask your clinician
  • Have I been evaluated by a pain management specialist?
  • Have I tried gabapentin, pregabalin, duloxetine, or amitriptyline for neuropathic pain?
  • Have I had pain psychology or cognitive-behavioral therapy?
  • Am I a candidate for nerve block, peripheral nerve stimulation, or neuromodulation?
  • What evidence specifically supports leech therapy for postsurgical pain?
  • Is leech application safe near my surgical mesh or hardware?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Spreading redness, warmth, pus, or red streaks near the surgical scar (possible deep infection)
  • Sudden severe pain, swelling, or fever (possible hardware or mesh infection)
  • New numbness, weakness, or loss of function
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for chronic postsurgical pain syndrome.
  • Small uncontrolled reports in neighbouring populations do NOT establish efficacy versus multimodal pharmacologic and physical therapy.
  • It does NOT address neuropathic pain mechanisms that drive most chronic postsurgical pain.
  • It does NOT substitute for pain psychology, cognitive-behavioral therapy, or interventional procedures.
  • It does NOT mean leech application is safe near surgical hardware, mesh, or prosthetics.

Clinical Profile

Category
Other
ICD-10
G89.21, G89.28, G89.4
Safety tier
Medium

Evidence Summary

Chronic postsurgical pain (CPSP) is pain persisting beyond 3 months after surgery, not attributable to other causes. Common in thoracotomy, mastectomy, inguinal hernia repair, amputation, and cesarean section. Evidence-based multimodal management: pharmacotherapy with gabapentinoids and serotonin-norepinephrine reuptake inhibitors for neuropathic features, NSAIDs for inflammatory features, topical lidocaine or capsaicin, physical therapy with scar mobilization, and (for refractory cases) interventional pain procedures including peripheral nerve blocks, neuroma injection, or spinal cord stimulation. No study of leech therapy in chronic postsurgical pain was identified in PubMed, Europe PMC or ClinicalTrials.gov. Two uncontrolled observations in neighbouring populations appear only in the Russian monograph by Baskova and Isakhanyan (2004): Sulim (1997) applied leeches to 27 patients with post-traumatic limb stumps and reported that pain resolved in all, and Sulim and Volokitin (2003) reported pain resolution in 18 patients after surgery for lower-limb gunshot wounds, with softer scars in 15. Both are conference reports without control groups, and neither is a CPSP cohort. Direct placement requires caution if the wound is recent (<6 months) or if the scar is keloid-prone.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Recent surgery (<6 months) or unhealed wound
  • Active surgical site infection or seroma
  • Suspected suture or implant pathology
  • Underlying tumor recurrence in the surgical bed (oncology workup first)
  • Implanted device near placement site (pacemaker, port, ICD)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.